Nebivolol  (Synonyms: 奈必洛尔; R 065824)

Nebivolol (R 065824) is an orally active beta receptor blocker and has the high beta(1)-receptor affinity. Nebivolol has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease^[1][2].

Nebivolol improves endothelial dysfunction via its strong stimulatory effects on the activity of the endothelial nitric oxide synthase and via its antioxidative properties^[1].
Nebivolol (0.1 μM-10 μM, 1, 2, 4, 7 or 14 days) inhibits haCSMC or haEC proliferation with IC₅₀ values of ~ 6.0 μM^[2].
Nebivolol (0.1 μM-10 μM, 24 h) induces a moderate rate of apoptosis^[2].
Nebivolol (0.1, 1, 5,10 μM, 4 days)increases NO formation and decreases endothelin-1 secretion in HaCEs^[2]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

405.44

C₂₂H₂₅F₂NO₄

118457-14-0

奈必洛尔

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Thomas Münzel, et al. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009 Oct 13;54(16):1491-9.  [Content Brief]

  [2]. Brehm BR, et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res. 2001 Feb 1;49(2):430-9.  [Content Brief]